Schedule 13D ownership disclosure

Zenas Biopharma Inc

Common Stock, $0.0001 par value · CUSIP: 98937L105

Event date: 2025-10-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SR One Capital Management, LLCReported CIK 0001853723

    Shares: 5,037,854 · Class: 9.4%

  • SR One Capital Fund II Aggregator, LP

    Shares: 1,946,564 · Class: 3.6%

  • SR One Capital Partners II, LP

    Shares: 1,946,564 · Class: 3.6%

  • AMZL, LP

    Shares: 1,917,895 · Class: 3.6%

  • SR One Capital SMA Partners, LP

    Shares: 1,917,895 · Class: 3.6%

  • SR One Capital Opportunities Fund I, LP

    Shares: 1,173,395 · Class: 2.2%

  • SR One Capital Opportunities Partners I, LP

    Shares: 1,173,395 · Class: 2.2%

  • Simeon George

    Shares: 5,037,854 · Class: 9.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-239173
Form type
SCHEDULE 13D/A
Filer
SR ONE CAPITAL MANAGEMENT, LLC
CIK
CIK 1853723
Filed
Oct 14, 2025
Reporting period
Oct 09, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub